Molecular and clinical aspects of the effect of cytidyndiphosphocholine on cognitive functions

Gromova O.A.; Torshin I.Yu.; Grishina T.R.; Demidov V.I.; Bogacheva T.E.

doi:https://doi.org/10.17116/jnevro202112105188

Close metadata

OBJECTIVE

Systematization of the array of publications on cytidyldiphosphocholine (CDP-choline).

MATERIAL AND METHODS

Systematic computer analysis of all currently available publications on CDP-choline (1750 publications in PUBMED) using the topological theory of big data analysis.

RESULTS

CDP-choline is essential for acetylcholine biosynthesis, phospholipid metabolism, and DNA methylation. The article describes the effects of CDP-choline on acetylcholinergic and other types of neurotransmission, anti-inflammatory, neuroprotective and neurotrophic effects of CDP-choline. Also, the paper presents the effects of the molecule on lipid metabolism and gene expression within the post-genomic paradigm (in particular, an increase in the expression of nicotinic and muscarinic acetylcholine receptors). The results of fundamental and clinical studies of CDP-choline in the treatment of cognitive impairments associated with cerebral ischemia and neurodegeneration are presented.

CONCLUSION

The pharmacological effects of CDP-choline are mediated through multiple molecular mechanisms that contribute to the nootropic action of this molecule.

Keywords:

cognitive disorders

molecular pharmacology

citicoline

neipilept

Authors:

Gromova O.A.

Federal Research Center «Computer Science and Control»

ORCID: 0000-0002-7663-710X

Torshin I.Yu.

Federal Research Center «Computer Science and Control»

ORCID: 0000-0002-2659-7998

Grishina T.R.

Ivanovo State Medical Academy of the Ministry of Health of Russia

Demidov V.I.

Ivanovo State Medical Academy of the Ministry of Health of Russia

Bogacheva T.E.

Ivanovo State Medical Academy of the Ministry of Health of Russia

Received:

02.03.2021

Accepted:

28.03.2021

Close metadata

References:

Parfenov V. A. Vascular cognitive disorders and chronic cerebral ischemia (dyscirculatory encephalopathy). Neurology, neuropsychiatry, psychosomatics. 2019;11(3S):61-67. https://doi.org/10.14412/2074-2711-2019-3S-61-67
Torshin I. Yu., Gromova O. A. Expert data analysis in molecular pharmacology. 2012;748.
Barrachina M, Domínguez I, Ambrosio S, Secades J, Lozano R, Ferrer I. Neuroprotective effect of citicoline in 6-hydroxydopamine-lesioned rats and in 6-hydroxydopamine-treated SH-SY5Y human neuroblastoma cells. J Neurol Sci. 2003;215(1-2):105-110. PMID: 14568136. https://doi.org/10.1016/s0022-510x(03)00204-1
Torshin I. Yu., Gromova O. A., Stakhovskaya L. V., Semenov V. A., https://doi.org/10.14412/2074-2711-2020-4-91-99
Torshin IYu, Rudakov KV. On the Theoretical Basis of Metric Analysis of Poorly Formalized Problems of Recognition. Patt Rec Image Anal. 2015;25:4:577-587.
Torshin IYu, Rudakov KV. On metric spaces arising during formalization of recognition and classification problems. part 1: compactness. Patt Rec Image Anal. 2016;26:2:274.
Torshin IYu. Optimal Dictionaries output information based on the criterion of Solvability and their applications in Bioinformatics. Patt Rec Image Anal. 2013;23:2:319-327.
Torshin IYu, Rudakov KV. On the Procedures of Generation of Numerical Features Over Partitions of Sets of Objects in the Problem of Predicting Numerical Target Variables. Patt Rec Image Anal. 2019;29:4:654-667. https://doi.org/10.1134/S1054661819040175
Solovieva EY, Farrahova KI, Karneev AN, Chipova DT. Phospholipids metabolism disorders in acute stroke. Zh Nevrol Psikhiatr im. S.S. Korsakova. 2016;116(1):104-112. PMID:27045147. (In Russ.). https://doi.org/10.17116/jnevro201611611104-112
Amenta F, Di Tullio MA, Tomassoni D. The cholinergic approach for the treatment of vascular dementia: evidence from pre-clinical and clinical studies. Clin Exp Hypertens. 2002;24(7-8):697-713. PMID: 12450245. https://doi.org/10.1081/ceh-120015346
Putilina MV. A personalized selection of choline precursors in evidence — based medicine. Zh Nevrol Psikhiatr im. S.S. Korsakova. 2020;120(6):144-151. PMID: 32678562. (In Russ.). https://doi.org/10.17116/jnevro2020120061144
Uslu G, Savci V, Buyukuysal LR, Goktalay G. CDP-choline attenuates scopolamine induced disruption of prepulse inhibition in rats: involvement of central nicotinic mechanism. Neurosci Lett. 2014;569:153-157. https://doi.org/10.1016/j.neulet.2014.03.070
Choueiry J, Blais CM, Shah D, Smith D, Fisher D, Illivitsky V, Knott V. CDP-choline and galantamine, a personalized α7 nicotinic acetylcholine receptor targeted treatment for the modulation of speech MMN indexed deviance detection in healthy volunteers: a pilot study. Psychopharmacology (Berl). 2020 Aug 27. https://doi.org/10.1007/s00213-020-05646-1
Choueiry J, Blais CM, Shah D, Smith D, Fisher D, Illivitsky V, Knott V. Combining CDP-choline and galantamine: Effects of a selective α7 nicotinic acetylcholine receptor agonist strategy on P50 sensory gating of speech sounds in healthy volunteers. J Psychopharmacol. 2019;33(6):688-699. Epub 2019 Mar 28. PMID: 30920339. https://doi.org/10.1177/0269881119836217
Deutsch SI, Schwartz BL, Schooler NR, Brown CH, Rosse RB, Rosse SM. Targeting alpha-7 nicotinic neurotransmission in schizophrenia: a novel agonist strategy. Schizophr Res. 2013;148(1-3):138-144. Epub 2013 Jun 13. PMID: 23768813. https://doi.org/10.1016/j.schres.2013.05.023
Hamurtekin E, Bagdas D, Gurun MS. Possible involvement of supraspinal opioid and GABA receptors in CDP-choline-induced antinociception in acute pain models in rats. Neurosci Lett. 2007;420(2):116-121. https://doi.org/10.1016/j.neulet.2007.04.058.
Weiss GB. Metabolism and actions of CDP-choline as an endogenous compound and administered exogenously as citicoline. Life Sci. 1995;56(9):637-660. PMID: 7869846. https://doi.org/10.1016/0024-3205(94)00427-t
Giménez R, Raïch J, Aguilar J. Changes in brain striatum dopamine and acetylcholine receptors induced by chronic CDP-choline treatment of aging mice. Br J Pharmacol. 1991;104(3):575-578. PMID: 1839138. https://doi.org/10.1111/j.1476-5381.1991.tb12471.x
Saligaut C, Daoust M, Moore N, Boismare F. Effects of hypoxia and cytidine (5’) diphosphocholine on the concentrations of dopamine, norepinephrine and metabolites in rat hypothalamus and striatum. Arch Int Pharmacodyn Ther. 1987;285(1):25-33. PMID: 3579424.
Eberhardt R, Birbamer G, Gerstenbrand F, Rainer E, Traegner H. Citicoline in the treatment of Parkinson’s disease. Clin Ther. 1990;12(6):489-495. PMID: 2289218.
Agut J, Ortiz JA, Wurtman RJ. CDP-choline modulates dopamine-evoked K-release in striatum. Ann NY Acad Sci. 2000;920:332-335. https://doi.org/10.1111/j.1749-6632.2000.tb06944.x
Radad K, Gille G, Xiaojing J, Durany N, Rausch WD. CDP-choline reduces dopaminergic cell loss induced by MPP(+) and glutamate in primary mesencephalic cell culture. Int J Neurosci. 2007;117(7):985-998. PMID: 17613109. https://doi.org/10.1080/10623320600934341
Martinet M, Fonlupt P, Pacheco H. Effects of cytidine-5’ diphosphocholine on norepinephrine, dopamine and serotonin synthesis in various regions of the rat brain. Arch Int Pharmacodyn Ther. 1979;239(1):52-61. PMID: 485720.
Gromova O. A., Torshin I. Yu., Putilina M. V., Semenov V. A., Rudakov K. V. The choice of neuroprotective therapy in patients with chronic cerebral ischemia taking into account the synergism of drug interactions. Journal of Neurology and Psychiatry named after S. S. Korsakov. 2020;120(8):42-50. https://doi.org/10.17116/jnevro202012008142
Zazueta C, Buelna-Chontal M, Macías-López A, Román-Anguiano NG, González-Pacheco H, Pavón N, Springall R, Aranda-Frausto A, Bojalil R, Silva-Palacios A, Velázquez-Espejel R, Galvan Arzate S, Correa F. Cytidine-5’-Diphosphocholine Protects the Liver From Ischemia/Reperfusion Injury Preserving Mitochondrial Function and Reducing Oxidative Stress. Liver Transpl. 2018;24(8):1070-1083. PMID: 29679463. https://doi.org/10.1002/lt.25179
Torshin I. Yu., Gromova O. A., Kobalava Zh. D. On the repression of ω-3 polyunsaturated fatty acids by adepts of evidence-based medicine. Pharmacoeconomics. Modern Pharmacoeconomics and Pharmacoepiology. 2019;12(2):91-114. https://doi.org/10.17749/2070-4909.2019.12.2.91-114
Buelna-Chontal M, Franco M, Hernández-Esquivel L, Pavón N, Rodríguez-Zavala JS, Correa F, Jasso R, Pichardo-Ramos G, Santamaría J, González-Pacheco H, Soto V, Díaz-Ruíz JL, Chávez E. CDP-choline circumvents mercury-induced mitochondrial damage and renal dysfunction. Cell Biol Int. 2017;41(12):1356-1366. https://doi.org/10.1002/cbin.10871
Gutiérrez-Fernández M, Leciñana MA, Rodríguez-Frutos B, Ramos-Cejudo J, Roda JM, Díez-Tejedor E. CDP-choline at high doses is as effective as i.v. thrombolysis in experimental animal stroke. Neurol Res. 2012;34(7):649-656. https://doi.org/10.1179/1743132812Y.0000000058
Bagdas D, Sonat FA, Hamurtekin E, Sonal S, Gurun MS. The antihyperalgesic effect of cytidine-5’-diphosphate-choline in neuropathic and inflammatory pain models. Behav Pharmacol. 2011;22(5-6):589-598. PMID: 21836465. https://doi.org/10.1097/FBP.0b013e32834a1efb
Gurun MS, Parker R, Eisenach JC, Vincler M. The effect of peripherally administered CDP-choline in an acute inflammatory pain model: the role of alpha7 nicotinic acetylcholine receptor. Anesth Analg. 2009;108(5):1680-1687. https://doi.org/10.1213/ane.0b013e31819dcd08
Rejdak K, Rejdak R, Sieklucka-Dziuba M, Stelmasiak Z, Grieb P. The effects of citicoline and/or MK-801 on survival, neurological and behavioral outcome of mice exposed to transient hyperglycemia and oligemic hypoxia. Eur Neuropsychopharmacol. 2001;11(5):333-341. PMID: 11597819. https://doi.org/10.1016/s0924-977x(01)00107-9
Martynov MY, Gusev EI. Current knowledge on the neuroprotective and neuroregenerative properties of citicoline in acute ischemic stroke. J Exp Pharmacol. 2015;7:17-28. eCollection 2015. PMID: 27186142. https://doi.org/10.2147/JEP.S63544
Abdolmaleki A, Moghimi A, Ghayour MB, Rassouli MB. Evaluation of neuroprotective, anticonvulsant, sedative and anxiolytic activity of citicoline in rats. Eur J Pharmacol. 2016;789:275-279. Epub 2016 Jul 28. PMID: 27475676. https://doi.org/10.1016/j.ejphar.2016.07.048
Gutiérrez-Fernández M, Rodríguez-Frutos B, Fuentes B, Vallejo-Cremades MT. CDP-choline treatment induces brain plasticity markers expression in experimental animal stroke. Neurochem Int. 2012;60(3):310-317. https://doi.org/10.1016/j.neuint.2011.12.015
Başkaya MK, Doğan A, Rao AM, Dempsey RJ. Neuroprotective effects of citicoline on brain edema and blood-brain barrier breakdown after traumatic brain injury. J Neurosurg. 2000;92(3):448-452. PMID: 10701532. https://doi.org/10.3171/jns.2000.92.3.0448
Kim JH, Choi BY, Kho AR, Lee SH, Jeong JH, Hong DK, Lee SH, Sohn M, Ryu OH. Acetylcholine precursor, citicoline (cytidine 5’-diphosphocholine), reduces hypoglycaemia-induced neuronal death in rats. J Neuroendocrinol. 2018;30(1): 21-29. https://doi.org/10.1111/jne.12567
Silveri MM, Dikan J, Ross AJ, Jensen JE, Kamiya T, Kawada Y, Renshaw PF, Yurgelun-Todd DA. Citicoline enhances frontal lobe bioenergetics as measured by phosphorus magnetic resonance spectroscopy. NMR Biomed. 2008;21(10):1066-1075. https://doi.org/10.1002/nbm.1281
Hosseini-Sharifabad A, Rabbani M, Seyed-Yousefi Y, Safavi M. Magnesium Increases the Protective Effect of Citicoline on Aluminum Chloride-induced Cognitive Impairment. Clin Psychopharmacol Neurosci. 2020;18(2):241-248. https://doi.org/10.9758/cpn.2020.18.2.241
Krupinski J, Ferrer I, Barrachina M, Secades JJ, Mercadal J, Lozano R. CDP-choline reduces pro-caspase and cleaved caspase-3 expression, nuclear DNA fragmentation, and specific PARP-cleaved products of caspase activation following middle cerebral artery occlusion in the rat. Neuropharmacology. 2002;42(6):846-854. https://doi.org/10.1016/s0028-3908(02)00032-1
Takasaki K, Uchida K, Fujikawa R, Nogami A, Nakamura K, Kawasaki C, Yamaguchi K, Morita M, Morishita K, Kubota K, Katsurabayashi S. Neuroprotective effects of citidine-5-diphosphocholine on impaired spatial memory in a rat model of cerebrovascular dementia. J Pharmacol Sci. 2011;116(2):232-237. https://doi.org/10.1254/jphs.11013fp
Adibhatla RM, Hatcher JF. Citicoline decreases phospholipase A2 stimulation and hydroxyl radical generation in transient cerebral ischemia. J Neurosci Res. 2003;73(3):308-315. PMID: 12868064. https://doi.org/10.1002/jnr.10672
Krupinski J, Slevin M, Badimon L. Citicoline inhibits MAP kinase signalling pathways after focal cerebral ischaemia. Neurochem Res. 2005;30(8):1067-1073.
Krupinski J, Abudawood M, Matou-Nasri S, Al-Baradie R, Petcu EB, Justicia C, Planas A, Liu D, Rovira N. Citicoline induces angiogenesis improving survival of vascular/human brain microvessel endothelial cells through pathways involving ERK1/2 and insulin receptor substrate-1. Vasc Cell. 2012;4(1):20. PMID: 23227823. https://doi.org/10.1186/2045-824X-4-20
Hurtado O, Hernández-Jiménez M, Zarruk JG, Cuartero MI, Ballesteros I, Camarero G, Moraga A, Pradillo JM, Moro MA, Lizasoain I. Citicoline (CDP-choline) increases Sirtuin1 expression concomitant to neuroprotection in experimental stroke. J Neurochem. 2013;126(6):819-826. Epub 2013 May 13. PMID: 23600725. https://doi.org/10.1111/jnc.12269
Sun C, Zhang F, Ge X, Yan T, Chen X, Shi X, Zhai Q. SIRT1 improves insulin sensitivity under insulin-resistant conditions by repressing PTP1B. Cell Metab. 2007;6(4):307-319. PMID: 17908559. https://doi.org/10.1016/j.cmet.2007.08.014
Aslan E, Kocaeli H, Bekar A, Tolunay S, Ulus IH. CDP-choline and its endogenous metabolites, cytidine and choline, promote the nerve regeneration and improve the functional recovery of injured rat sciatic nerves. Neurol Res. 2011;33(7):766-773. PMID: 21756558. https://doi.org/10.1179/1743132811Y.0000000004
Oshitari T, Yoshida-Hata N, Yamamoto S. Effect of neurotrophic factors on neuronal apoptosis and neurite regeneration in cultured rat retinas exposed to high glucose. Brain Res. 2010;1346:43-51. https://doi.org/10.1016/j.brainres.2010.05.073
Rema V, Bali KK, Ramachandra R, Chugh M, Darokhan Z, Chaudhary R. CDP-choline in early life induces stable increase in dendritic complexity of neurons in the somatosensory cortex of adult rats. Neuroscience. 2008;155(2):556-564. https://doi.org/10.1016/j.neuroscience.2008.04.017
Fogagnolo P, Melardi E, Tranchina L, Rossetti L. Topical citicoline and vitamin B12 versus placebo in the treatment of diabetes-related corneal nerve damage: a randomized double-blind controlled trial. BMC Ophthalmol. 2020;20(1):315. https://doi.org/10.1186/s12886-020-01584-w
Gandolfi S, Marchini G, Caporossi A, Scuderi G, Tomasso L, Brunoro A. Cytidine 5’-Diphosphocholine (Citicoline): Evidence for a Neuroprotective Role in Glaucoma. Nutrients. 2020;12(3):793. PMID: 32197303. https://doi.org/10.3390/nu12030793
Medical toxicology. National Leadership (ed. by E. A. Luzhnikov ). GEOTAR-Media; 2012.
Horrocks LA, Dorman RV, Dabrowiecki Z, Goracci G, Porcellati G. CDPcholine and CDPethanolamine prevent the release of free fatty acids during brain ischemia. Prog Lipid Res. 1981;20:531-534. PMID: 7342106. https://doi.org/10.1016/0163-7827(81)90093-x
O’Dwyer C, Yaworski R, Katsumura S, Ghorbani P, Gobeil Odai K, Nunes JRC, LeBlond ND, Sanjana S, Smith TTK, Han S, Margison KD, Alain T, Morita M, Fullerton MD. Hepatic Choline Transport Is Inhibited During Fatty Acid-Induced Lipotoxicity and Obesity. Hepatol Commun. 2020;4(6):876-889. https://doi.org/10.1002/hep4.1516
Liu Y, Wang W, Shui G, Huang X. CDP-diacylglycerol synthetase coordinates cell growth and fat storage through phosphatidylinositol metabolism and the insulin pathway. PLoS Genet. 2014;10(3):e1004172. eCollection 2014 Mar. https://doi.org/10.1371/journal.pgen.1004172
Zhao JJ, Liu Y, Chen XL, Liu JX, Tian YF, Zhang PB, Kang QY, Qiu F. Effect of citicoline on spatial learning and memory of rats after focal cerebral ischemia. Nan Fang Yi Ke Da Xue Xue Bao. 2006;26(2):174-176. PMID: 16503522.
Alvarez-Sabín J, Román GC. The role of citicoline in neuroprotection and neurorepair in ischemic stroke. Brain Sci. 2013;3(3):1395-1414. https://doi.org/10.3390/brainsci3031395
Mashin VV, Belova LA, Dudikov EM, Bergelson TM, Lankov VA, Zakuraeva KA. The efficacy of recognan in the early stage of ischemic stroke. Zh Nevrol Psikhiatr im. S.S. Korsakova. 2017;117(10):44-48. MID: 29171488. (In Russ.). https://doi.org/10.17116/jnevro201711710144-48
Cho HJ, Kim YJ. Efficacy and safety of oral citicoline in acute ischemic stroke: drug surveillance study in 4,191 cases. Methods Find Exp Clin Pharmacol. 2009;31(3):171-176. PMID: 19536360. https://doi.org/10.1358/mf.2009.31.3.1364241
Alvarez-Sabín J, Santamarina E, Maisterra O, Jacas C, Molina C, Quintana M. Long-Term Treatment with Citicoline Prevents Cognitive Decline and Predicts a Better Quality of Life after a First Ischemic Stroke. Int J Mol Sci. 2016;17(3):390. https://doi.org/10.3390/ijms17030390
Secades JJ, Alvarez-Sabín J, Castillo J, Díez-Tejedor E, Martínez-Vila E, Ríos J, Oudovenko N. Citicoline for Acute Ischemic Stroke: A Systematic Review and Formal Meta-analysis of Randomized, Double-Blind, and Placebo-Controlled Trials. J Stroke Cerebrovasc Dis. 2016;25(8):1984-1996. Epub 2016 May 24. https://doi.org/10.1016/j.jstrokecerebrovasdis.2016.04.010
Mashin VV, Belova LA, Bakhtogarimov IR, Bergelson TM, Sharafutdinova RR. Multicenter observational program for evaluation of the effectiveness of the recognan (citicoline) in the correction of cognitive impairment in patients with chronic cerebrovascular pathology. Zh Nevrol Psikhiatr im S.S. Korsakova. 2017;117(8):39-43. PMID: 28884715. (In Russ.). https://doi.org/10.17116/jnevro20171178139-43
Alvarez XA, Laredo M, Corzo D, Fernández-Novoa L, Mouzo R, Perea JE, Daniele D, Cacabelos R. Citicoline improves memory performance in elderly subjects. Methods Find Exp Clin Pharmacol. 1997;19(3):201-210. PMID: 9203170.
Nemkova SA, Semenov DV, Petrova EA, Savchenko DV, Zavadenko NN, Vozvyshaeva MY, Kanishcheva AS, Ralleva AV, Logvinova EM, Tsvetkov DA, Charikova EV, Romanenko NI, Zagaryan DA, Boldyrev VG. Cognitive and emotional disorders in university students and teachers: the possibility of treatment with recognan (citicoline). Zh Nevrol Psikhiatr im. S.S. Korsakova. 2018;118(12):11-18. (In Russ.). https://doi.org/10.17116/jnevro201811812111
Alvarez XA, Mouzo R, Pichel V, Pérez P, Laredo M, Fernández-Novoa L, Corzo L, Zas R, Alcaraz M, Secades JJ. Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer’s disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion. Methods Find Exp Clin Pharmacol. 1999;21(9):633-644.
Piamonte BLC, Espiritu AI, Anlacan VMM. Effects of Citicoline as an Adjunct Treatment for Alzheimer’s Disease. J Alzheimers Dis. 2020;76(2):725-732. https://doi.org/10.3233/JAD-200378
Solovyeva EY, Karneev AN, Chekanov AV, Baranova OA. The individual and combined antioxidant effects of citicoline and ethylmethylhydroxypyridini succinas. Zh Nevrol Psikhiatr im. S.S. Korsakova. 2016;116(11):78-85. https://doi.org/10.17116/jnevro201611611178-85